EntryPoint Capital LLC Purchases New Shares in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

EntryPoint Capital LLC purchased a new position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 116,645 shares of the company’s stock, valued at approximately $624,000. EntryPoint Capital LLC owned 0.18% of Corvus Pharmaceuticals at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its stake in shares of Corvus Pharmaceuticals by 22.4% in the third quarter. Geode Capital Management LLC now owns 563,009 shares of the company’s stock worth $2,974,000 after acquiring an additional 102,869 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Corvus Pharmaceuticals in the 3rd quarter valued at approximately $265,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Corvus Pharmaceuticals by 64.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 137,031 shares of the company’s stock valued at $724,000 after buying an additional 53,809 shares during the last quarter. State Street Corp boosted its stake in shares of Corvus Pharmaceuticals by 48.2% during the 3rd quarter. State Street Corp now owns 178,246 shares of the company’s stock valued at $941,000 after buying an additional 57,943 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Corvus Pharmaceuticals in the third quarter worth $74,000. Institutional investors and hedge funds own 46.64% of the company’s stock.

Corvus Pharmaceuticals Trading Down 1.4 %

Shares of NASDAQ CRVS opened at $4.25 on Tuesday. The company has a market capitalization of $273.09 million, a price-to-earnings ratio of -4.57 and a beta of 0.91. Corvus Pharmaceuticals, Inc. has a twelve month low of $1.30 and a twelve month high of $10.00. The business has a 50 day simple moving average of $4.72 and a 200-day simple moving average of $6.10.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of Corvus Pharmaceuticals in a research note on Tuesday, January 14th. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.38.

Corvus Pharmaceuticals Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.